Jamie Udwadia, MD
Physical Medicine & Rehabilitation · Ahoskie, NCNPI 1255476636
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Smith+Nephew at 39.0% of the total. Reporting peaked in 2019 at $694 and has fallen 65.3% since, to $241 in 2025.
Across 115 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$950
- Organogenesis Inc.$290
- Collegium Pharmaceutical, Inc.$174
- Next Science LLC$127
- Mimedx Group, Inc.$100
- Solventum Corporation$92
- plus $703 from 24 others
What the payments were for
- Food & beverage$2,435100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 42 | $950 |
| Organogenesis Inc. | 7 | $290 |
| Collegium Pharmaceutical, Inc. | 14 | $174 |
| Next Science LLC | 5 | $127 |
| Mimedx Group, Inc. | 4 | $100 |
| Solventum Corporation | 4 | $92 |
| Osiris Therapeutics Inc. | 3 | $86 |
| Integra Lifesciences Corporation | 2 | $72 |
| Kerecis Limited | 4 | $62 |
| KCI USA, Inc. | 3 | $53 |
| Urgo Medical North America, LLC | 2 | $45 |
| AbbVie(2 entities) | 2 | $36 |
| OVIK Health, LLC | 1 | $35 |
| Pfizer | 3 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| AstraZeneca | 2 | $25 |
| Aroa Biosurgery Incorporated | 1 | $24 |
| Cashflow Solutions, LLC | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $18 |
| TEI Medical Inc. | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Pernix Therapeutics Holdings, Inc. | 1 | $14 |
| Stryker | 1 | $14 |
| Hartmann USA, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Shionogi Inc | 1 | $12 |
| Advanced Oxygen Therapy Inc. | 1 | $9 |
| Polarityte, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,435 in reported general payments places this provider in the 80th percentile of 269 physical medicine & rehabilitation providers in North Carolina.
See all physical medicine & rehabilitation providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 67 | $50,464 |
| Fentanyl | 224 | $27,478 |
| OxycontinOxycodone Hcl | 40 | $21,652 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 614 | $20,124 |
| Buprenorphine | 64 | $15,503 |
| LinzessLinaclotide | 27 | $13,971 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 474 | $11,217 |
| Oxycodone Hcl | 428 | $10,421 |
| MovantikNaloxegol Oxalate | 22 | $8,920 |
| SantylCollagenase Clostridium Hist. | 22 | $8,149 |
| Naloxone Hcl | 60 | $4,248 |
| Tramadol Hcl | 385 | $3,889 |
| Gabapentin | 238 | $3,015 |
| Cyclobenzaprine Hcl | 247 | $1,975 |
| Pregabalin | 48 | $1,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $174 | $50,46467 claims |
| AbbVieLinzess | $36 | $13,97127 claims |
| Smith+NephewSantyl | $950 | $8,14922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 269 physical medicine & rehabilitation providers in North Carolina.
Other physical medicine & rehabilitation in Ahoskie
- Andrew SumichCharlotte$181K
- Patrick O BrienRaleigh$86K
- Elizabeth BagsbyGreenville$33K
- Krishna BhatSanford$30K
- Jasbir DhaliwalSanford$23K
- Jimmy MaliDurham$20K
- Jerome WatsonStatesville$15K
- Tejas ParikhGastonia$14K
- Christopher GodboutCary$12K
- Graham McRaryHickory$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.